Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Hepatocellular carcinoma (HCC) is the sixth most common form of cancer worldwide. Although surgi‑ cal treatments have an acceptable cure rate, tumor recurrence is still a challenging issue. In this meta-analysis, we investigated whether statins prevent HCC recurrence following liver surgery. | Khajeh et al. BMC Cancer 2022 22 91 https doi.org 10.1186 s12885-022-09192-1 RESEARCH Open Access Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery Elias Khajeh1 Arash Dooghaie Moghadam1 Pegah Eslami1 Sadeq Ali Hasan Al Saegh1 Ali Ramouz1 Saeed Shafiei1 Omid Ghamarnejad1 Sepehr Abbasi Dezfouli1 Christian Rupp2 3 Christoph Springfeld3 4 Carlos Carvalho5 Pascal Probst1 Seyed Mostafa Mousavizadeh1 and Arianeb Mehrabi1 3 Abstract Background Hepatocellular carcinoma HCC is the sixth most common form of cancer worldwide. Although surgi cal treatments have an acceptable cure rate tumor recurrence is still a challenging issue. In this meta-analysis we investigated whether statins prevent HCC recurrence following liver surgery. Methods PubMed Web of Science EMBASE and Cochrane Central were searched. The Outcome of interest was the HCC recurrence after hepatic surgery. Pooled estimates were represented as hazard ratios HRs and odds ratios ORs using a random-effects model. Summary effect measures are presented together with their corresponding 95 confi dence intervals CI . The certainty of evidence was evaluated using the Grades of Research Assessment Development and Evaluation GRADE approach. Results The literature search retrieved 1362 studies excluding duplicates. Nine retrospective studies including 44 219 patients 2243 in the statin group and 41 976 in the non-statin group were included in the qualitative analysis. Patients who received statins had a lower rate of recurrence after liver surgery HR 0.53 95 CI 0.44 0.63 p Khajeh et al. BMC Cancer 2022 22 91 Page 2 of 9 have acceptable cure rates they also have high recur- excluded. The remaining studies were selected for full- rence rates 8 9 with recurrence in more than 50 of text review by reviewing the titles and abstracts for patients after 5 years of surgery 10 11 . Recurrence rates eligibility. after transplantation are between 8 and 21 despite the use of new .
